Top Myeloma Updates from EHA 2026: New Therapies, Trials & Emerging Treatments
Explore the latest multiple myeloma advances from EHA 2026, including updates in CAR-T therapy, bispecific and trispecific antibodies, BCMA and GPRC5D-directed treatments, MRD testing, and emerging treatment strategies. Discover the research shaping the future of myeloma care. If this video has helped you or a loved one, consider donating to HealthTree. Every donation helps us continue to create free and high-quality blood cancer educational content: https://give.healthtree.org/give/6286... For an organized lesson structure, watch on our site here: https://linktr.ee/HealthTreeUniversity Create a free account to track your progress, bookmark lessons, and keep up-to-date on the latest advancements in treating cancer! Patients have the key to find cures for cancer. Learn more about HealthTree's services here: https://healthtree.org/curehub?utm_so... Educated and empowered patients have better outcomes. We've partnered with hundreds of medical experts and doctors to help you learn more about your disease.
SUCCESSOR-2 Trial: Mezigdomide Triplet Shows Powerful Results in Relapse/Refractory Multiple Myeloma
MajesTEC-3: Teclistamab + Dara in Cytogenetic & Functional High Risk Relapsed Myeloma | EHA 2026
Is Multiple Myeloma Fatal? What Experts Say About Living a Normal Life
ASCO 2026 highlights advances in targeted therapies for molecularly driven NSCLC
Recent Advances in Multiple Myeloma with Dr. Dan Vogl
Struggling with Fatigue and Brain Fog? Solutions for People Living with Multiple Myeloma
These 7 Habits Raise Your Risk of Stroke and Heart Attack
FAQs: Immunotherapy for Multiple Myeloma: Exploring Options Through Your Disease Journey
ASCO 2026 GU Highlights & FDA Approvals with Drs. Brian Rini & Tom Powles (The Uromigos)
How to Use Methylation Supplements Safely If You Have MTHFR
Can Blood Draws Replace Bone Marrow Biopsies? The Promise of Circulating Tumor Cells in Myeloma
Relapsed/Refractory Multiple Myeloma Highlights from EHA | EHA 2026
Your Multiple Myeloma Lab Results, Decoded: What They Mean and What They Don’t
TRIlogy-4: Ramantamig’s Triple Target Attack on Myeloma—BCMA, GPRC5D, and CD3 #EHA2026
5 Things That Surprise People Most About Hip Replacement
Myeloma 101: Understanding Multiple Myeloma, Risk Factors, Diagnosis & Treatments Explained
Lower Infections with Elranatamab in Multiple Myeloma in Real-World Settings | EHA 2026
The Lenalidomide Patch for Myeloma: What Do We Know?
How is MRD (measurable residual disease) used as a surrogate endpoint in clinical trials? #myeloma
